Regulation Of Human Gene Editing Research Funding Restrictions Germany

Introduction

Human gene editing research involves modifying genetic material in human cells using technologies such as CRISPR-Cas9. In Germany, public funding for this research is subject to strict legal, ethical and scientific conditions. The regulatory approach distinguishes between editing somatic cells, which affects the treated individual, and editing the germline, which may transmit genetic changes to future generations.

Germany does not have one statute that comprehensively prohibits all human gene-editing research funding. Instead, restrictions arise from the Embryo Protection Act, the Stem Cell Act, the Genetic Engineering Act, EU rules, research-funding conditions and constitutional principles. Funding agencies must ensure that proposed projects comply with these requirements before awarding or releasing grants.

Legal Framework Governing Research Funding

The Embryo Protection Act 1990 (Embryonenschutzgesetz – ESchG) is central to restrictions on embryo-related gene editing. Section 2 prohibits certain improper uses of human embryos. Section 2(1), in particular, restricts the sale or use of an embryo for purposes other than its preservation. Section 5 regulates artificial alteration of human germline genetic information and prohibits certain interventions involving germline cells.

The precise scope of Section 5 is important. It does not create a general prohibition on every form of genetic research involving human cells. Its restrictions concern artificial alteration of human germline information and specified uses of germline cells. Consequently, research funding involving embryos or reproductive cells requires careful legal assessment.

The Stem Cell Act 2002 (Stammzellgesetz – StZG) regulates the import and use of human embryonic stem cells for research. It generally prohibits importing or using embryonic stem cells unless statutory conditions are satisfied. These include approval by the competent authority, a qualifying research purpose, compliance with ethical requirements and restrictions relating to the origin and date of the stem-cell lines. The Robert Koch Institute performs the relevant approval function.

The Genetic Engineering Act (Gentechnikgesetz – GenTG) primarily regulates genetic engineering activities involving organisms and contained facilities, as well as certain releases into the environment. It may apply to laboratory activities involving genetically modified biological material. However, it should not be treated as a general legal authorisation for editing human embryos or germline cells.

Restrictions on Public and Institutional Funding

Public funding bodies, including federal research institutions and research-support programmes, must assess whether proposed projects comply with German law and applicable ethical standards. Funding cannot lawfully be used to support activities prohibited by the ESchG or StZG.

The following distinctions are particularly important:

Somatic gene editing: Research involving non-reproductive human cells may be eligible for funding, subject to medical, clinical-trial, biosafety and ethical requirements.

Germline editing: Projects involving prohibited interventions in human germline cells face significant legal restrictions under Section 5 ESchG.

Embryonic stem-cell research: Funding involving imported embryonic stem cells must comply with the StZG and its approval requirements.

Clinical research: Projects involving medicinal products or advanced therapy medicinal products must comply with applicable EU pharmaceutical legislation and German clinical-trial requirements.

The German Research Foundation (Deutsche Forschungsgemeinschaft – DFG) and other research-funding institutions also apply scientific integrity and ethical-review requirements. These institutional standards may restrict funding even where a proposed activity is not expressly prohibited by legislation.

The EU's Horizon Europe Regulation (EU) 2021/695 also imposes ethical limitations on research funding. Article 18 and the programme's ethical requirements exclude certain activities, including research intended to modify the genetic heritage of human beings where such changes could become heritable, subject to the regulation's stated exceptions. EU funding conditions therefore operate alongside German national law.

Ethical Review and Regulatory Oversight

Research institutions must examine the scientific purpose, proportionality, foreseeable risks and potential consequences of gene-editing projects. Ethics committees may assess research involving human participants, embryos or sensitive biological materials.

For clinical investigations involving gene-editing medicinal products, Regulation (EU) 536/2014 on clinical trials and applicable German implementing legislation are relevant. Gene therapies may also fall within the EU Advanced Therapy Medicinal Products framework under Regulation (EC) 1394/2007.

Funding approval does not replace regulatory authorisation. A grant recipient must obtain all necessary approvals before conducting regulated research.

Relevant Case Laws

1. Brüstle v Greenpeace e.V. (Case C-34/10, 2011)

The Court of Justice of the European Union interpreted the EU Biotechnology Directive and considered the meaning of human embryos in relation to patentability. The judgment is relevant to embryo-related biotechnology because it demonstrates the importance of ethical restrictions surrounding human embryonic material. It was a patent-law decision, not a direct ruling on research grants or gene-editing funding.

2. International Stem Cell Corporation v Comptroller General (Case C-364/13, 2014)

The Court clarified the meaning of a human embryo under the Biotechnology Directive, particularly concerning parthenogenetically activated human ova. The decision is relevant when determining the legal treatment of biological materials used in research, although it does not directly determine German funding eligibility.

3. Costa and Pavan v Italy (Application No. 54270/10, 2012)

The European Court of Human Rights examined restrictions on preimplantation genetic diagnosis under Article 8 of the European Convention on Human Rights. The judgment demonstrates that reproductive genetic regulation must consider private and family life. It provides relevant human-rights context for decisions about reproductive gene-editing research, but it does not establish a direct funding entitlement.

Conclusion

Germany applies strict legal and ethical controls to human gene-editing research funding, particularly where projects involve human embryos or heritable genetic modification. The ESchG and StZG establish important national restrictions, while EU research-funding rules and pharmaceutical regulations provide additional safeguards. Somatic gene-editing research may receive funding if it satisfies applicable legal and ethical requirements. However, funding approval cannot legitimise research activities prohibited by law.